Last updated: February 21, 2026
Summary:
Cortef (hydrocortisone), a corticosteroid used for inflammation and adrenal insufficiency, is produced by multiple pharmaceutical companies globally. The primary suppliers are major generic drug manufacturers and branded drug producers, with notable market players including Pfizer, Teva Pharmaceutical Industries, Sandoz, and Sun Pharmaceutical Industries. The supply chain involves both branded and off-patent formulations, with generic manufacturers dominating due to patent expirations.
Who Are the Leading Suppliers of Cortef (Hydrocortisone)?
| Manufacturer |
Product Name |
Formulation |
Market Regions |
Manufacturing Location |
| Pfizer (formerly Upjohn) |
Cortef |
Oral tablets |
U.S., Europe, Asia |
U.S., Germany |
| Teva Pharmaceutical Industries |
Hydrocortisone |
Oral tablets, injections |
Global, especially U.S. and Europe |
Israel, global manufacturing sites |
| Sandoz (a Novartis division) |
Hydrocortisone |
Oral tablets, injections |
Europe, U.S., emerging markets |
Switzerland, regional locations |
| Sun Pharmaceutical Industries |
Hydrocortisone |
Oral, topical formulations |
Asia, North America, Europe |
India, U.S., Egypt |
| Pharmacia & Upjohn (Pfizer legacy) |
Cortef |
Oral tablet |
U.S., established presence |
U.S. |
Market Dynamics and Supply Chain
Patent and Regulatory Status
Hydrocortisone formulations, including Cortef, are off-patent, enabling multiple manufacturers to produce generic versions. Patent expirations in the late 1990s and early 2000s led to increased generic entrants. Regulatory approval processes, including FDA and EMA approvals, ensure quality and bioequivalence across products.
Manufacturing and Supply Risks
Supply continuity depends on manufacturing capacity, regulatory compliance, and geopolitical stability. Supply disruptions have occurred due to capacity shortages, quality issues, or trade restrictions. The rise of regional generic makers in India and Eastern Europe contributes to increased supply diversity.
Market Share and Pricing
Major suppliers control significant market segments; Pfizer historically held a large share but has decreased market dominance post-generic emergence. Generic competition drives prices down, with average wholesale prices (AWP) for hydrocortisone tablets ranging from $0.05 to $0.15 per tablet, depending on dosage and manufacturer.
Supply Chain Consolidation and Competition
Ongoing consolidation in the generic segment, with mergers and acquisitions, influences supplier options. Key recent developments include Sandoz expanding its hydrocortisone product line through new formulations and geographic entry.
Regional Market Breakdown
| Region |
Leading Suppliers |
Market Features |
| United States |
Pfizer, Teva, Sandoz, Sun Pharmaceutical |
Competitive, high-volume market with abundant generic options |
| Europe |
Sandoz, Teva, Pfizer, local manufacturers |
Stringent regulatory environment; mix of branded and generics |
| Asia-Pacific |
Sun Pharma, local Indian manufacturers |
Cost-sensitive, growing regulatory rigor, expanding exports |
| Middle East & Africa |
Sun Pharma, local producers, regional suppliers |
Emerging markets with drug import reliance |
Key Takeaways
- Multiple global manufacturers supply hydrocortisone, with Pfizer and Teva leading in market presence.
- The product's patent expiry has led to extensive generic competition, diminishing prices.
- Regional manufacturers, especially in India and Eastern Europe, supplement supply chains.
- Supply risks involve capacity constraints, regulatory hurdles, and geopolitical factors.
- Lower-cost generics have increased access across emerging markets, influencing global distribution dynamics.
FAQs
Q1: Which companies are the primary producers of Cortef in the U.S.?
A1: Pfizer and Teva are the leading suppliers of hydrocortisone products, including Cortef, in the U.S.
Q2: Are there non-branded equivalents of Cortef?
A2: Yes, numerous generic manufacturers produce hydrocortisone tablets and injections, which are bioequivalent to Cortef.
Q3: Has the patent expiration affected the supply and price of Cortef?
A3: Yes, patent expirations opened the market to generics, increasing competition and decreasing prices.
Q4: Which regions have the most diverse supplier options?
A4: North America and Europe have the most diverse suppliers due to mature markets and regulatory frameworks.
Q5: Are there recent supply disruptions for hydrocortisone products?
A5: There have been occasional shortages caused by manufacturing capacity issues, quality reviews, or supply chain disruptions in regional markets.
References
- FDA Drug Approvals and Labeling. (2022). Food and Drug Administration.
- European Medicines Agency. (2022). Marketing authorization holders for hydrocortisone.
- IMS Health. (2021). Global Pharmaceutical Market Data Report.
- Sandoz Official Website. (2023). Product portfolio.
- Pfizer Annual Report. (2022). Pfizer Inc.
